Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Top Page
Blueprint Medicines
(NASDAQ:BPMC)
48Neutral
Positive Factors
International Expansion
Management expects Ayvakit reimbursement in more EU countries, which could increase ex-US revenues.
Investor Confidence
The stock finished the day up 11% due to raised guidance and meeting revenue expectations, signaling investor confidence.
Revenue Guidance
Management raised FY25 Ayvakit revenue guidance to $700-720mn, indicating confidence in future performance.
Negative Factors
Competitive Concerns
Shares are performing better than expected, driven by positive setup for the remainder of the year and alleviating competitive concerns.
Sales Lumpiness
Management suggested that ex-U.S. performance reflected sales lumpiness rather than a slowing of underlying ex-U.S. demand growth.
Blueprint Medicines (BPMC) vs. S&P 500 (SPY)
Market Cap
$6.76B
Dividend YieldN/A
Average Volume (3M)1.11M
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth99.19%
EPS Growth48.43%
CountryUS
Employees682
SectorHealthcare
Sector Strength60
IndustryBiotechnology
Share Statistics
EPS (TTM)0.01
Shares Outstanding64,582,160
10 Day Avg. Volume969,398
30 Day Avg. Volume1,109,088
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.33
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$127.94Price Target Upside29.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Blueprint Medicines Business Overview & Revenue Model
Company DescriptionBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyBlueprint Medicines generates revenue primarily through the sales of its approved therapies, such as AYVAKIT/AYVAKYT, which are marketed for specific indications in the United States and Europe. Additionally, the company earns revenue through collaboration and licensing agreements with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on the sales of partnered products. Significant partnerships, such as those with Genentech and CStone Pharmaceuticals, contribute to its earnings by expanding the reach and development of its products in various markets. Moreover, Blueprint Medicines invests in research and development to continually innovate and expand its pipeline of targeted therapies, which supports long-term revenue growth.
Blueprint Medicines Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and indicating strategic focus areas.
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and indicating strategic focus areas.
Data provided by:
Main Street Data
Main Street DataBlueprint Medicines Financial Statement Overview
Summary
Blueprint Medicines shows notable revenue growth, but ongoing challenges with profitability and cash flow management persist. The balance sheet is stable with manageable debt, yet there's a need for improved efficiency and cost management to achieve profitability.Income Statement
Blueprint Medicines has shown a notable increase in revenue over recent years, indicating strong growth potential with a revenue growth rate of 10.46% TTM. However, the company remains unprofitable with a negative net profit margin of -27.69% and negative EBIT and EBITDA margins, reflecting ongoing challenges in cost management and operational efficiency.40
Negative
Balance Sheet
The company's balance sheet shows a moderate debt-to-equity ratio of 0.36 TTM, indicating manageable debt levels. However, the return on equity remains problematic at -45.51%, reflecting negative profitability. The equity ratio of 28.62% suggests a stable asset base, although the reliance on equity financing could be improved.50
Neutral
Cash Flow
Blueprint Medicines faces challenges with cash flow, as indicated by negative free cash flow and a deteriorating free cash flow growth rate of 23.45% TTM. The operating cash flow to net income ratio is negative, highlighting cash flow pressures and the need for improved cash management strategies.35
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 508.82M | 249.38M | 204.04M | 180.08M | 793.74M | Gross Profit |
| 488.66M | 236.58M | 186.22M | 162.15M | 793.31M | EBIT |
| -212.04M | -486.28M | -549.25M | -648.46M | 302.15M | EBITDA |
| 19.23M | -470.36M | -515.41M | -628.30M | 308.71M | Net Income Common Stockholders |
| -67.09M | -506.98M | -557.52M | -644.09M | 313.88M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 615.49M | 710.64M | 1.08B | 1.03B | 1.55B | Total Assets |
| 1.18B | 1.05B | 1.35B | 1.25B | 1.72B | Total Debt |
| 469.11M | 774.12M | 242.45M | 111.41M | 89.60M | Net Debt |
| 367.09M | 702.84M | 122.74M | -98.54M | -595.03M | Total Liabilities |
| 881.15M | 918.64M | 835.23M | 281.49M | 248.31M | Stockholders Equity |
| 298.67M | 130.61M | 514.68M | 970.74M | 1.47B |
| Cash Flow | Free Cash Flow | |||
| -197.22M | -452.91M | -511.20M | -559.89M | 383.88M | Operating Cash Flow |
| -192.59M | -436.85M | -502.28M | -298.65M | 387.04M | Investing Cash Flow |
| -47.50M | 274.04M | -149.54M | -225.86M | -434.25M | Financing Cash Flow |
| 273.11M | 119.22M | 561.81M | 50.72M | 617.76M |
Blueprint Medicines Technical Analysis
Positive
99.16
Price Trends
88.48
Positive
93.99
Positive
93.86
Positive
Market Momentum
2.89
Negative
70.14
Negative
93.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPMC, the sentiment is Positive. The current price of 99.16 is above the 20-day moving average (MA) of 86.64, above the 50-day MA of 88.48, and above the 200-day MA of 93.86, indicating a bullish trend. The MACD of 2.89 indicates Negative momentum. The RSI at 70.14 is Negative, neither overbought nor oversold. The STOCH value of 93.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BPMC.
Blueprint Medicines Risk Analysis
Blueprint Medicines disclosed 71 risk factors in its most recent earnings report. Blueprint Medicines reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Blueprint Medicines Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $5.24B | 14.95 | 25.71% | ― | -12.31% | -17.53% | |
66 Neutral | $6.24B | 26.71 | 19.71% | ― | 52.97% | ― | |
57 Neutral | $7.32B | ― | 35.68% | ― | -41.71% | -9.37% | |
54 Neutral | $5.52B | ― | -282.16% | ― | 42.53% | -15.29% | |
52 Neutral | $7.57B | ― | -29.33% | ― | -100.00% | 5.49% | |
52 Neutral | $5.35B | 3.83 | -41.61% | 2.85% | 17.10% | 1.22% | |
48 Neutral | $6.76B | ― | -47.71% | ― | 99.19% | 48.43% |
* Healthcare Sector Average
Performance Comparison
BPMC
Blueprint Medicines
99.16
-9.39
-8.65%
ALKS
Alkermes
31.40
6.81
27.69%
SRPT
Sarepta Therapeutics
46.75
-89.29
-65.64%
AXSM
Axsome Therapeutics
112.16
35.22
45.78%
BBIO
BridgeBio Pharma
36.94
9.15
32.93%
RVMD
Revolution Medicines
37.44
-1.44
-3.70%
Blueprint Medicines Earnings Call Summary
Earnings Call Date:May 01, 2025
(Q1-2025)
| % Change Since: 10.79%|
Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment Positive
Despite some challenges in the first quarter and international markets, Blueprint Medicines shows strong performance with significant revenue growth, successful pipeline advancements, and a solid financial position. The sentiment is largely positive, driven by the strong market reception of AYVAKIT and increased revenue guidance.Q1-2025 Updates
Positive Updates
AYVAKIT Revenue Growth
Blueprint Medicines achieved 61% year-over-year AYVAKIT revenue growth, capturing substantial commercial opportunities in systemic mastocytosis.
Raised Revenue Guidance
Due to strong performance and favorable dynamics, Blueprint Medicines raised its AYVAKIT net product revenue guidance to $700 million to $720 million for the year.
Pipeline Advancements
Initiated two proof-of-concept studies for BLU-808 in allergic rhinoconjunctivitis and chronic urticaria. Elenestinib showed potential best-in-disease profile with ongoing pivotal Harbor study.
Strong Cash Position
Blueprint Medicines maintains a strong cash position of $900 million, allowing continued investment in R&D and commercial initiatives.
Positive Market Reception
AYVAKIT has been well-received by both providers and patients, with over 95% of patients expressing high satisfaction, and prescriber base has tripled since ISM approval.
Negative Updates
Challenging First Quarter Dynamics
Typical first quarter insurance dynamics and fewer ordering days impacted gross to net, though this was anticipated and managed.
Limited International ISM Reimbursement
Currently, Germany is the only ex-US market with ISM reimbursement. Other international markets are still in pricing and reimbursement negotiations.
Potential Free Goods Rate Uncertainty
While the free goods rate is currently well below 10%, future Medicare patients' access to commercial therapy could be impacted by foundation funding availability.
Company Guidance
During the Blueprint Medicines 1Q 2025 earnings call, the company reported a 61% year-over-year increase in AYVAKIT revenue, contributing to total revenues of $149.4 million for the quarter. The revenue breakdown included $129.4 million from the U.S. and $20 million from ex-U.S. markets. Due to strong performance and favorable dynamics, Blueprint raised its revenue guidance for the year to a range of $700 million to $720 million. The company highlighted the significant potential of its two prioritized pipeline programs, elenestinib and BLU-808, and their progress in clinical trials, including the initiation of two proof-of-concept studies for BLU-808. Blueprint's strategic focus remains on expanding its prescriber base, particularly among allergists, dermatologists, and gastroenterologists, and increasing patient starts, aiming for a $2 billion revenue goal for AYVAKIT by 2030.Blueprint Medicines Corporate Events
Business Operations and StrategyFinancial Disclosures
Blueprint Medicines Highlights 2024 Achievements and Future Growth
Positive
Jan 13, 2025
Blueprint Medicines Corporation announced updates to its corporate presentation for the investment community, emphasizing its growth strategies and operational excellence. The company highlighted its achievements in 2024, including significant revenue growth for AYVAKIT, the expansion of its global reach, and advancements in drug development, positioning itself for continued innovation and market expansion in 2025.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.